Leiomyoma
Drug research and approvals for leiomyoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 44 studies of leiomyoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 44
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 2
- Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large UteriNCT07895953 · Not reported · University Hospital, Strasbourg, France · starts Mar 20, 2026
- Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic SurgeryNCT07860203 · Not applicable · Catherin Zhang · starts Oct 1, 2026
- Artificial Intelligence Into Ultrasound Diagnostics in Reproductive MedicineNCT07810920 · Not reported · Semmelweis University · starts Sep 1, 2026
- Safety and Efficacy of Microwave Ablation Alone Versus Microwave Ablation Combined With Chemical Ablation in the…NCT07754877 · Not applicable · Peking University Aerospace Center Hospital · starts Aug 1, 2026
- Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES HysterectomyNCT07730970 · Not applicable · Fatih Sultan Mehmet Training and Research Hospital · starts Jul 1, 2026
- Cyclobenzaprine for Postoperative Pain in Minimally Invasive HysterectomyNCT07664956 · Phase 4 · Christiana Care Health Services · starts Sep 1, 2026
- FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid RecurrenceNCT07647198 · Phase 2 · Sheikh Shakhbout Medical City · starts Aug 22, 2026
- Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical TourniquetNCT07526311 · Not applicable · Cairo University · starts Apr 10, 2026
- TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk PatientsNCT07480785 · Not applicable · Zhejiang University · starts Jan 16, 2026
Approved 1
- LinzagolixGonadotropin-releasing hormone receptor antagonist
Phase 3 12 of 13
- Telapristone acetateProgesterone receptor modulator
- AsoprisnilProgesterone receptor modulator
- VilaprisanProgesterone receptor modulator
- MifepristoneGlucocorticoid receptor antagonist
- LeuprolideGonadotropin-releasing hormone receptor agonist
- RelugolixGonadotropin-releasing hormone receptor antagonist
- MisoprostolProstanoid EP3 receptor agonist
- ProgesteroneProgesterone receptor agonist
- Epigalocatechin gallate
- Tranexamic acidPlasminogen inhibitor
- GoserelinGonadotropin-releasing hormone receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 2 9
- UlipristalProgesterone receptor modulator
- Dienogest
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- LidocaineSodium channel alpha subunit blocker
- SimvastatinHMG-CoA reductase inhibitor
- RopivacaineSodium channel alpha subunit blocker
- VasopressinVasopressin receptor agonist
- Pirfenidone
- AcetylcysteineGlutathione precursor
Phase 1 or earlier 4
- PF-05019702Progesterone receptor antagonist
- LetrozoleCytochrome P450 19A1 inhibitor
- ClomipheneEstrogen receptor alpha modulator
- CarbetocinOxytocin receptor agonist
How its trials ended
443 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 122 whose ending is known, 38% met their primary endpoint, 4% missed it and 58% stopped early.
- Completed, result not reported17239%
- Status unknown7918%
- Ongoing7016%
- Met its primary endpoint4610%
- Stopped: other or unclear327%
- Stopped: enrollment or feasibility164%
- Stopped: sponsor or business decision123%
- Stopped: lack of efficacy61%
- Missed its primary endpoint51%
- Stopped: funding51%
| Dec 19, 2013 | A randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of ulipristal acetate for the treatment of abnormal…Fibristal | Teva Pharmaceutical Industries | Pending |
| Aug 21, 2013 | A randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of ulipristal acetate for the intermittent treatment of…Fibristal | AbbVie | Ongoing |
| Jun 14, 2022 | YseltyLinzagolix choline | Theramex Ireland Limited | EMA ↗ |
| Jul 16, 2021 | RyeqoRelugolix; estradiol; norethisterone acetate | Gedeon Richter Plc. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA